Mersana Therapeutics (MRSN) said Friday initial clinical data from the phase 1 study of its lead candidate, emiltatug ledadotin, targeting B7-H4, showed clinical activity across multiple tumor types and was well tolerated among patients.
The company said the dose escalation portion of the trial enrolled 130 patients with advanced/metastatic cancers, including types of breast cancer, ovarian cancer, and endometrial cancer. Many patients were heavily pretreated, with a median of 4.5 prior therapy lines.
The drugmaker said that the confirmed objective response rate at intermediate doses was 23% across all B7-H4 high tumors and 23% in B7-H4 high TNBC patients.
At higher doses, the objective response rate was 22%, with 78% of patients showing 30% or more tumor reduction in target lesions, it added.
Mersana said it will continue to explore higher doses and implement proteinuria mitigation strategies.
Shares of the company rose 20% in premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.